Paperonium

← Back to the plain-language case

Abstract reports 84% of ST2621 isolates as clinical; the Results count gives 98 of 164 (60%)

PLoS Pathog (2026) · doi:10.1371/journal.ppat.1013859 · PMC12810914

Summary

The abstract says that most isolates of the dominant clone ST2621 came from adult patients (59%) and from clinical samples (84%). The Results section, describing the same 164 ST2621 isolates, gives 95 adult (58%) and 98 clinical (60%) isolates, and the isolate-level S1 Table reproduces those counts exactly. An 84% clinical share would need 137 or 138 clinical ST2621 isolates. That is incompatible with the Results count, and also with the paper's own totals: Table 1 lists 186 clinical isolates in the whole collection, which leaves room for at most 135 clinical ST2621 isolates. The direction of the finding (most ST2621 isolates were clinical) is unchanged, but the abstract overstates the clinical share by 24 percentage points in the sentence that describes the clone.

What the paper reports

All quotes are from the article as archived in PubMed Central and were checked verbatim.

Abstract:

Sequence type (ST) 2621 (164, 40%) and ST39 (164, 40%) predominated with several minor STs making up the remainder. The majority of ST2621 associated with blaOXA-181 were isolated from adult patients (59%) and clinical samples (84%).

Results, first MLST paragraph:

ST2621 and ST39 were overwhelmingly dominant in the collection (S1 Table), represented by 164 isolates (39.6%) each.

Results, "Characteristics of ST2621":

blaOXA-181 was the predominant carbapenemase gene associated with this ST, being detected in all isolates, with one isolate having an additional blaNDM–1 gene.

The majority of the ST2621 isolates were from adult patients (95, 58%) and from clinical samples (98, 60%).

Results, carbapenemase genes (counts used for the upper bound below):

The predominant genes were blaOXA-181 (194, 46.9%) and blaNDM-1 (191, 46.2%).

Interestingly, most isolates with blaNDM-1 were from carriage samples (146, 72.6%), whereas those with blaOXA-181 were mostly clinical isolates (125, 64.4%) (Fig 1C).

Results, ST48 paragraph:

All ST48 isolates were blaOXA-181 producers, except for the first ST48 isolate from 2019, which produced blaOXA-48 (Fig 2). This ST was predominantly in adult patients (16, 84.2%) and from clinical samples (15, 79.0%).

Results, "Characteristics of ST39":

The majority of the ST39 isolates were obtained from neonatal (92, 56.1%) and paediatric (64, 39.0%) patients and mostly in carriage samples (128, 78.0%).

Table 1, "Source" rows (total isolates n = 778 | stored isolates n = 413):

Clinical | 357 (45.9) | 186 (45.0)
Carriage | 421 (54.1) | 227 (55.0)

Discussion:

In contrast, ST2621 was more associated with adult patients and clinical samples. Given that limited CRE colonization screening was undertaken in the adult wards, this almost certainly presents an underestimation of the true spread, and the propensity to cause more disease cannot be quantified sufficiently.

What the paper's own numbers show

Method. I divided the Results counts for ST2621 by the stated clone size (164) and found which integer counts out of 164 round to the abstract's percentages. I then bounded the number of clinical ST2621 isolates in two ways that use only counts printed in the text: (A) the 186 clinical isolates in Table 1, minus the clinical isolates of ST39 (164 − 128 carriage = 36) and ST48 (15); and (B) the 125 clinical blaOXA-181 isolates, since the Results say all ST2621 isolates carry blaOXA-181, minus at least 14 clinical blaOXA-181 isolates of ST48 (15 clinical ST48 isolates, of which at most one is the single blaOXA-48 isolate). Finally, I recounted the isolate-level rows of S1 Table (supplementary file s006, sheet "metadata_PRJEB63349"), stripping trailing spaces from six cells. Every number below is printed by recompute.py.txt.

Quantity Location Reported Recomputed from the paper's own numbers
ST2621 from clinical samples Abstract 84% 98/164 = 59.8%; 84% of 164 needs 137 or 138 isolates
ST2621 from clinical samples Results, "Characteristics of ST2621" 98, 60% 98/164 = 59.8% (consistent)
ST2621 from adult patients Abstract 59% 95/164 = 57.9%; 59% needs 96 or 97 isolates
ST2621 from adult patients Results, "Characteristics of ST2621" 95, 58% 95/164 = 57.9% (consistent)
Ceiling A on clinical ST2621 Table 1; ST39 and ST48 paragraphs 186 clinical in all 186 − 36 − 15 = 135, so at most 135/164 = 82.3%; 137 + 36 + 15 = 188 and 138 + 36 + 15 = 189, both above 186
Ceiling B on clinical ST2621 blaOXA-181 and ST48 paragraphs 125 clinical blaOXA-181 isolates at most 125/164 = 76.2%; after subtracting ST48, at most 111/164 = 67.7%
ST2621 counts in S1 Table S1 Table, isolate rows — n = 164: 95 adult (57.9%), 54 paediatric, 15 neonate; 98 clinical (59.8%), 66 screening (40.2%)
ST2621 with OXA-181 in the class D column S1 Table — n = 147: 89 adult (60.5%), 92 clinical (62.6%)
Clinical share among ST2621 adults S1 Table cross-tabulation — 78/95 = 82.1% (74/89 = 83.1% in the OXA-181 subset)
Adult share among ST2621 clinical isolates S1 Table cross-tabulation — 78/98 = 79.6%
ST48 adults Results, ST48 paragraph 16, 84.2% 16/19 = 84.2% (the same rounded value as the abstract's 84%)
ST39 carriage, neonatal, paediatric Abstract vs Results, "Characteristics of ST39" 76%, 57%, 38% vs 128 (78.0%), 92 (56.1%), 64 (39.0%) 128/164 = 78.0%, 92/164 = 56.1%, 64/164 = 39.0%

The Results percentages agree with their own counts and with the supplement. The abstract's 84% does not match any ST2621 quantity in the paper or the supplement, and it is also larger than the most clinical ST2621 isolates the paper's totals can hold (ceiling A, 82.3%). Ceiling A uses only the Table 1 total and the per-ST counts in the text, not the gene data. S1 Table has 187 clinical rows in the whole collection rather than 186. Using 187 in ceiling A gives 136/164 = 82.9%, still below 84%.

Figure

Abstract and Results give different clinical shares for the same 164 ST2621 isolates

Figure 1. The two conflicting sentences, quoted verbatim. Left: the abstract's percentages, as printed (orange). Right: the percentages computed from the counts printed in the Results sentence (blue): 98 of 164 clinical (59.8%) and 95 of 164 adult (57.9%). The clinical shares differ by 24.2 percentage points. An 84% share would need 137 or 138 clinical isolates, while the Results give 98 and the Table 1 totals leave room for at most 135.

The abstract's 84% lies above the largest clinical share the paper's own totals allow

Figure 2. Share of the 164 ST2621 isolates that came from clinical samples, on a 0–100% axis. The orange dot is the abstract value (84%; dashed reference line). The blue dot is the Results count (98/164 = 59.8%). The blue bars show the largest values the paper's other counts permit: 135/164 = 82.3% from the Table 1 total of 186 clinical isolates minus the clinical isolates of ST39 (36) and ST48 (15), and 111/164 = 67.7% from the 125 clinical blaOXA-181 isolates, if, as the Results state, every ST2621 isolate carries blaOXA-181, minus at least 14 clinical blaOXA-181 isolates of ST48. The abstract value lies above both ceilings.

Why it matters

Explanations considered

Status

As of 2026-10-24:

Suggested correction

In the abstract, replace

The majority of ST2621 associated with blaOXA-181 were isolated from adult patients (59%) and clinical samples (84%).

with wording consistent with the Results and S1 Table, for example:

The majority of ST2621 isolates, which carried blaOXA-181, were from adult patients (95/164, 58%) and clinical samples (98/164, 60%).

The authors may also wish to: